Because of characteristic balanced translocation t(12;15) in SBC, further research for a specific NTRK3 tyrosine kinase inhibitor could lead to the discovery of a new targeted treatment of this tumor [16,17]. This evidence concerns the gene NTRK3 and neoplasm.